J.J.P. Kastelein

1.7k total citations · 1 hit paper
30 papers, 1.2k citations indexed

About

J.J.P. Kastelein is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, J.J.P. Kastelein has authored 30 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Surgery, 11 papers in Endocrinology, Diabetes and Metabolism and 10 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in J.J.P. Kastelein's work include Lipoproteins and Cardiovascular Health (15 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (9 papers) and Lipid metabolism and disorders (7 papers). J.J.P. Kastelein is often cited by papers focused on Lipoproteins and Cardiovascular Health (15 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (9 papers) and Lipid metabolism and disorders (7 papers). J.J.P. Kastelein collaborates with scholars based in Netherlands, United States and Canada. J.J.P. Kastelein's co-authors include Dick C.G. Basart, Mojgan Yazdanpanah, Joep C. Defesche, Eric J.G. Sijbrands, J. C. M. Witteman, Jan Heeringa, Daniëlla M. Oosterveer, Anho Liem, Jorie Versmissen and Peter Lansberg and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and European Heart Journal.

In The Last Decade

J.J.P. Kastelein

30 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy of statins in familial hypercholesterolaemia: a long term cohort study

2008 524 citations Jorie Versmissen, Daniëlla M. Oosterveer et al. BMJ profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J.J.P. Kastelein Netherlands	15	835	427	319	254	178	30	1.2k
Michael Stepanavage United States	11	905 1.1×	540 1.3×	242 0.8×	254 1.0×	167 0.9×	16	1.3k
Paul Ziajka United States	11	1.0k 1.2×	499 1.2×	315 1.0×	271 1.1×	228 1.3×	18	1.3k
M van Linde-Sibenius Trip Netherlands	8	706 0.8×	480 1.1×	401 1.3×	216 0.9×	122 0.7×	8	1.2k
Antonio J. Vallejo‐Vaz Spain	19	877 1.1×	469 1.1×	369 1.2×	282 1.1×	172 1.0×	51	1.5k
Damon A. Bell Australia	23	1.1k 1.3×	528 1.2×	357 1.1×	300 1.2×	286 1.6×	100	1.6k
Mogens Lytken Larsen Denmark	14	723 0.9×	478 1.1×	286 0.9×	191 0.8×	161 0.9×	32	1.0k
Jong-Soon Park United States	12	793 0.9×	632 1.5×	375 1.2×	133 0.5×	171 1.0×	27	1.7k
Greg Brown United States	3	1.3k 1.6×	755 1.8×	573 1.8×	264 1.0×	162 0.9×	3	1.8k
Peter H. Jones United States	9	780 0.9×	349 0.8×	302 0.9×	174 0.7×	220 1.2×	13	1.1k
David Neff United States	17	938 1.1×	394 0.9×	269 0.8×	233 0.9×	299 1.7×	39	1.4k

Countries citing papers authored by J.J.P. Kastelein

Since Specialization

Citations

This map shows the geographic impact of J.J.P. Kastelein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J.J.P. Kastelein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J.J.P. Kastelein more than expected).

Fields of papers citing papers by J.J.P. Kastelein

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J.J.P. Kastelein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J.J.P. Kastelein. The network helps show where J.J.P. Kastelein may publish in the future.

Co-authorship network of co-authors of J.J.P. Kastelein

This figure shows the co-authorship network connecting the top 25 collaborators of J.J.P. Kastelein. A scholar is included among the top collaborators of J.J.P. Kastelein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J.J.P. Kastelein. J.J.P. Kastelein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sivapalaratnam, Suthesh, S. Matthijs Boekholdt, Mieke D. Trip, et al.. (2010). Family history of premature coronary heart disease and risk prediction in the EPIC-Norfolk prospective population study. Heart. 96(24). 1985–1989. 76 indexed citations

Holme, Ingar, Rana Fayyad, Ole Færgeman, et al.. (2009). Cardiovascular outcomes and their relationships to lipoprotein components in patients with and without chronic kidney disease: results from the IDEAL trial. Journal of Internal Medicine. 267(6). 567–575. 21 indexed citations

Rana, Jamal S., Benoît J. Arsenault, Jean‐Philippe Després, et al.. (2009). Inflammatory biomarkers, physical activity, waist circumference, and risk of future coronary heart disease in healthy men and women. European Heart Journal. 32(3). 336–344. 95 indexed citations

Hassing, H. Carlijne, Th.B. Twickler, J.J.P. Kastelein, Maarten J. Cramer, & Flemming R. Cassee. (2009). Air pollution as noxious environmental factor in the development of cardiovascular disease.. PubMed. 67(4). 116–21. 18 indexed citations

Versmissen, Jorie, Daniëlla M. Oosterveer, Mojgan Yazdanpanah, et al.. (2008). Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ. 337(nov11 1). a2423–a2423. 524 indexed citations breakdown →

Kastelein, J.J.P., et al.. (2008). COMPARISON OF EFFECTS OF TORCETRAPIB AND RO4607381/JTT-705 ON BLOOD PRESSURE AND TISSUE EXPRESSION OF RENIN-ANGIOTENSIN SYSTEM-RELATED GENES IN RATS. Atherosclerosis Supplements. 9(1). 42–42. 1 indexed citations

Leuven, Sander I. van, et al.. (2005). Mycophenolate mofetil (MMF): Firing at the atherosclerotic plaque from different angles?. Cardiovascular Research. 69(2). 341–347. 36 indexed citations

Scholten, Harm J., et al.. (2005). W17-P-003 Reproducibility of B-mode ultrasound brachial flow mediated dilation measurements. Atherosclerosis Supplements. 6(1). 126–126. 1 indexed citations

Rodenburg, Jessica, Albert Wiegman, Maud N. Vissers, J.J.P. Kastelein, & Anton F. H. Stalenhoef. (2004). A boy with autosomal recessive hypercholesterolaemia.. PubMed. 62(3). 89–93. 15 indexed citations

10.

Birjmohun, Rakesh S., Barbara A. Hutten, J.J.P. Kastelein, & Erik S.G. Stroes. (2004). Increasing HDL cholesterol with extended-release nicotinic acid: from promise to practice.. PubMed. 62(7). 229–34. 49 indexed citations

11.

Dam, Marjel van, Sanne van Wissen, & J.J.P. Kastelein. (2002). Declaring War on Undertreatment: Rationale for an Aggressive Approach to Lowering Cholesterol. European Journal of Cardiovascular Prevention & Rehabilitation. 9(2). 89–95. 12 indexed citations

12.

Dam, Marjel van, Anton F. H. Stalenhoef, Janneke Wittekoek, et al.. (2001). Efficacy of Concentrated n-3 Fatty Acids in Hypertriglyceridaemia. Clinical Drug Investigation. 21(3). 175–181. 8 indexed citations

13.

Smilde, Tineke J., Mieke D. Trip, Hub Wollersheim, et al.. (2000). Rationale, Design and Baseline Characteristics of a Clinical Trial Comparing the Effects of Robust vs Conventional Cholesterol Lowering and Intima Media Thickness in Patients with Familial Hypercholesterolaemia. Clinical Drug Investigation. 20(2). 67–79. 28 indexed citations

14.

Stalenhoef, Anton F. H., Jacqueline de Graaf, Marianne E. Wittekoek, et al.. (2000). The effect of concentrated n-3 fatty acids versus gemfibrozil on plasma lipoproteins, low density lipoprotein heterogeneity and oxidizability in patients with hypertrygliceridemia. Atherosclerosis. 153(1). 129–138. 81 indexed citations

15.

Prins, J. A., et al.. (1998). The Functional and Clinical Significance of the Met→Thr Substitution in Kringle IV Type 10 of Apolipoprotein(a). Thrombosis Research. 90(3). 125–130. 4 indexed citations

16.

Hansen, Peter S., J.J.P. Kastelein, Lars Ulrik Gerdes, et al.. (1997). Phenotypic Variation in Patients Heterozygous for Familial Defective Apolipoprotein B (FDB) in Three European Countries. Arteriosclerosis Thrombosis and Vascular Biology. 17(4). 741–747. 38 indexed citations

17.

Bijvoet, Saskia M., Heiko Wiebusch, Yuxuan Ma, et al.. (1996). Compound heterozygosity for a known and a novel defect in the lipoprotein lipase gene (Asp250 ? Asn; Ser251 ? Cys) resulting in lipoprotein lipase (LPL) deficiency. The Netherlands Journal of Medicine. 49(5). 189–195. 14 indexed citations

18.

Bijvoet, Saskia M., C Gagné, Jean‐Charles Fruchart, et al.. (1994). Heterozygous lipoprotein lipase (LPL) deficiency: lipid and apolipoprotein composition of lipoproteins suggest increased risk for coronary heart disease. Atherosclerosis. 109(1-2). 62–63. 1 indexed citations

19.

Bruin, T., et al.. (1991). Hindlll-polymorphism in the LPL-gene detected by PCR. Nucleic Acids Research. 19(22). 6346–6346. 10 indexed citations

20.

Funke, Harald, Arnold von Eckardstein, P. Haydn Pritchard, et al.. (1991). A molecular defect causing fish eye disease: an amino acid exchange in lecithin-cholesterol acyltransferase (LCAT) leads to the selective loss of alpha-LCAT activity.. Proceedings of the National Academy of Sciences. 88(11). 4855–4859. 101 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact